RESUMO
To determine serum endoglin [CD 105] levels in cases of prostatic cancer and benign prostate hyperplasia Also, to evaluate its role in the diagnosis and prognosis of prostate cancer. This study included 70 patients and 12 normal control individuals. Measurement of serum PSA was performed for cases of prostate cancer and benign prostatic hyperplasia [BPH] while measurement of serum endoglin was performed for all patients and control individuals. These cases were classified into 3 groups. Group I included 42 patients with prostate cancer, the criteria for diagnosis were digital rectal examination [DRE] of irregular abnormal hard nodule/ nodules in the prostate or PSA > 4 ng /ml. The diagnosis wits confirmed by trans- rectal ultrasouand [TRUS] biopsy. According to Gleason's score, these patients were further classified into Grade II and III. Group II included 28 patients with benign prostatic hyperplasia [BPH].Group III included 12 healthy men as control group. Serum CD 105 concentration was estimated by using human endolin ELISA kit. There was a significant difference in PSA levels prostate cancer [mean 32.4 +/- 30.85 ng/ml] BPH [mean 2.84 +/- 1.67 ng/ml]. The mean values of CD 105 were 5.29, 2.12 and 0.15 ne/ml in group I, II and III [controls], respectively. The mean value of CD 105 in each group was significantly different from the other groups. In group I. the mean value of CD 105 of' grade III was 7.5 ng/ml and was significantly higher than that [4.89 ng/ml] of grade II prostate cancer. There was a significant correlation between CD 105 and PSA levels in prostate cancer. It was found that the cut of serum endoglin was 2.65 ng/ml for diagnosis of cancer prostate. Endoglin [CD105] has a critical role in the diagnosis and prognosis of cases of prostate cancer and it can be used as a marker for diagnosis of these cases